Steffen Koschmieder

63PUBLICATIONS
224CO-AUTHORS
Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (63)

|Jul 15, 2026
JAK2V617F-positive clonal hematopoiesis in germline BRCA1 versus BRCA2 mutation carriers.

|Jun 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|Jun 03, 2026
Type I interferon-activated NK cells control polycythemia vera in vivo.

|Apr 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

|Jan 06, 2026
Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms.

Robert Meyer, Maria Jimena Rodriguez, Madeline Caduc

|Nov 26, 2025
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.

Ruth-Miriam Koerber, Calvin Krollmann, Kevin Cieslak

Pageof 11

Frequent Collaborators

12 joint publications

Nicolas Chatain

10 joint publications

Tim Henrik Brümmendorf

10 joint publications

Francesca Palandri

9 joint publications

Tiziano Barbui